CureVac

News
CureVac

GSK goes all-in on CureVac’s mRNA vaccines

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and

News
CureVac1

CureVac and GSK try again with COVID-19 vaccine

CureVac and GlaxoSmithKline's first attempt to develop a COVID-19 vaccine was a salutary reminder of the pitfalls in drug development, as the mRNA shot crashed and burned in a clinical tria